DBV to make new approval bid for VIASKIN Peanut on Phase III trial
DBV received a complete response letter from the FDA in August 2020, citing adhesion and efficacy concerns with the patch.
17 December 2025
17 December 2025
DBV received a complete response letter from the FDA in August 2020, citing adhesion and efficacy concerns with the patch.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.